The results suggest that D-dimer plasma levels might be useful to predict the clinical outcome and survival of patients with lung cancer.
The emergence of drug resistance is a major problem for tuberculosis (TB) control. The aim of this study was to determine the rates of resistance against TB drugs in patients with pulmonary tuberculosis (PTB). Data from 387 patients with active PTB between the years of 1999 and 2004 from the Research and Education Hospital for Chest Diseases and Chest Surgery were evaluated retrospectively. The patients were categorized as new, re-treatment, extrapulmonary and chronic cases. The study group consisted of 268 (69%) new, 57 (14.7%) re-treatment, 49 (12.6%) extrapulmonary and 13 (3.3%) chronic TB cases. The rates of resistance to isoniazid (INH), rifampicin (R), ethambutol (E) and streptomycin (S) were calculated separately for each group. The resistance to any of the drugs was 7.8% in the new cases, 58.5% in the re-treatment cases and 100% in the chronic cases. The multidrug-resistance (MDR)-TB rates were found to be 2.16%, 11.3% and 92.3% among the new, re-treatment and chronic cases, respectively. These data are important as they reflect the drug resistance rates during the pre-notification time period in western Turkey.
A sixty-three-year-old man who had had Hodgkin lymphoma twenty years earlier and laryngeal mucosa associated lymphatic tissue lymphoma (MALToma) two years earlier and had been treated with radiotherapy and chemotherapy was admitted to our ward with cough and hemoptysis. Physical examination revealed decreased breath sounds on the left hemitorax incomparison to the right. On chest x-ray and thoracic CT, at the left hilar region, there was a 6x5x5cm-sized, malignant-appearing mass with invasion to the hilar vascular structures. An endobronchial lesion was seen on fiberoptic bronchoscopy. The histology of the biopsy specimen was reported as squamous cell carcinoma. The patient was treated with chemotherapy and radiotherapy with the diagnosis of stage 3B lung carcinoma and is still on treatment. We want to present this case with literature reviews, as lymphoma, MALToma and carcinoma in the same patient is extremely rare. (Tur Toraks Der 2010; 11: 187-90) ÖZETYirmi y l önce Hodgkin lenfoma tan s ve iki y l önce larinks mukoza ile ili kili lenfatik doku lenfomas (MALToma) tan s ile radyoterapi, kemoterapi alm ve tedavisini tamamlayarak, kür elde edilmi olan, altm üç ya nda erkek hasta öksürük ve kanl balgam ikayeti ile servisimize yat r ld . Fizik muayenesinde sol hemitoraksta sa a göre solunum sesleri az al nd . Akci er grafisi ve toraks BT' de sol hiler bölgede, 6x5x5cm çapl , malign görünümlü, hiler vasküler yap lara invaze kitle lezyonu izlendi. Hastaya bronkoskopi yap ld ve endobron iyal lezyon izlendi. Biyopsi patoloji sonucu skuamöz hücreli karsinom olarak raporland . Hastaya evre 3B akci er karsinomu tan s ile kemoterapi ve radyoterapi uyguland ve halen tedavisi sürmektedir. Ayn hastada lenfoma, MALToma ve karsinoma birlikteli inin nadir görülmesi nedeniyle, literatür bilgileri e li inde sunmay uygun bulduk. (Tur Toraks Der 2010; 11: 187-90) Anahtar sözcükler: Hodgkin lenfoma, MALToma, akci er kanseri
Introduction: Euthanasia has taken its place again in discussion agenda after the legal arrangements permitting active euthanasia in the Netherlands and Belgium were made. Physicians' views, especially of those working in the field of oncology, are very important in revealing the views on euthanasia. Our study was conducted to show the approach of the pulmonologists heavily working in the field of oncology in Turkey. Materials and Methods:In our survey study, 110 physicians working in pulmonary medicine in Turkey were accessed, and the data were assessed By SPSS program. Results:The mean age of the pulmonologists participating in our study was 32.90±7.01 years, and 40.8 % of these stated not being against euthanasia. Of the participants, 22.7 % stated encountering " wish for euthanasia", and 46.7 % stated believing that euthanasia is being performed hiddenly though for bidden. Conclusion:The views on euthanasia and patient rights of the physicians attending terminal-stage patients are very important. The participating physicians frequently encountering "wish for euthanasia" and their extensive beliefs about that euthanasia is being performed hiddenly shows this issue should absolutely be discussed in our country.
Background: Mediastinal lymph node metastasis is one of the most principal prognostic factors in lung cancer treatment. N2 patients have a poor prognosis compared to N1, N0 cases. Histological diagnosis of mediastinal lymph node metastasis is necessary for the indication of surgery. There are several methods to examine the mediastinal lymphadenopathy, such as mediastinoscopy, endobronchial ultrasoundguided trans-bronchial needle aspiration (EBUS-TBNA) and etc. but it is neither practical nor clinically possible, however, to use mediastinoscopy or EBUS for all patients with primary lung cancer. Methods: A prospective phase II study of indications for surgery, using video-assisted mediastinoscopy (VAM) and EBUS-TBNA to detect mediastinal lymph node metastasis was conducted in patients with resectable primary lung cancer of clinical stages I-IIIA. Indications for VAM were based on tumor size, CT findings and tumor markers, and patients were placed in group V ( VAM or EBUS) or group A ( thoracotomy without VAM) accordingly. EBUS-TBNA was performed if the CT findings showed mediastinal lymph nodes larger than 15 mm in the shortest axis. Mediastinal lymph node involvement confirmed by VAM or EBUS was treated with chemotherapy followed by thoracotomy (group C) or radiotherapy (group D), and cases without detected metastasis underwent thoracotomy and systematic lymph node dissection (group B). Group A patients had primary tumor resection and lymph node sampling and group C patients, tumor resection and extended dissection of mediastinal lymph nodes via median sternotomy. Results: Of the 500 eligible cases who were introduced to our center between Oct. 1998 and Des.2006, 249 underwent VAM (group V) and 217 had thoracotomy without VAM (group A). EBUS-TBNA was indicated for 34 patients. Of the VAM patients, 189 negative patients for metastasis received thoracotomy and 60 positive cases received 2 courses of chemotherapy and 28 responders received thoracotomy and 32 non-responders received radiation or best supportive care. Twelve negative cases by EBUS-TBNA received thoracotomy and 22 positive cases received chemotherapy. Six responders received thoracotomy and 16 non-responders received radiation. The two-and 5-year survival rates of groups A, and B were 94.8%, and 90.0% (group A), and 90.8% and 59.1% (group B), respectively, while the 2-year rate in Group C was 68.0%. Conclusions:We have demonstrated the usefulness of indication criteria for VAM and EBUS for the selection of candidates for primary lung cancer surgery. These indication criteria enabled us to avoid doing valueless examinations and to avoid unnecessary thoracotomy. The more favorable group A outcomes indicated both successful selection by these criteria of patients not requiring mediastinal examination, and superfluity of complete lymph node dissection, proper lymph nodes sampling being sufficient for staging.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.